Novel, small molecule FX11a inhibitors

Home / Novel, small molecule FX11a inhibitors
Novel, small molecule FX11a inhibitors
    • Product Overview: First in class molecules for effective anti-coagulation with minimal associated risk of bleeding
    • Primary Indication(s): Prevention of VTE in susceptible patients, (for example patients undergoing orthopaedic surgery, medically ill patients, those with non-valvular atrial fibrillation, patients with acute symptomatic DVT or PE
    • Secondary Indications: SPAF, Secondary prevention of cardiac events associated with ACS, Treatment of DVT & PE and prevention of recurrent DVT & PE in adults; Prevention of stroke
    • Core differentiators:
      1. First and only FXIIa inhibitors in development
      2. Highly effective anti-coagulation with minimal bleeding risk
      3. Wide therapeutic window
      4. Reduced monitoring requirement
      5. Availability of an antidote
    • Development Stage: Lead Optimisation
    • Company/ Institution: University of Leeds; leeds.ac.uk (www.medhealth.leeds.ac.uk/profile/500/256/helen_philippou/1)
    • Opportunity: Available for license and sponsored research